<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03564470</url>
  </required_header>
  <id_info>
    <org_study_id>PDT-Ph-Like</org_study_id>
    <nct_id>NCT03564470</nct_id>
  </id_info>
  <brief_title>Precision Diagnosis Directing HDACi and TKI Target Therapy for Adult Ph-like ALL</brief_title>
  <official_title>An Open-Label, One-Arm, Multi-Site Trial of Precision Diagnosis Directing Target Total Therapy for Adult Ph-like Acute Lymphoblastic Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nanfang Hospital of Southern Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nanfang Hospital of Southern Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Ph-like ALL is a recently recognized high-risk subgroup and the optimal therapeutic
      approaches are poorly characterized. Based on the pediatric-inspired,
      PEG-L-asparaginase-intensified and MRD-directed PDT-ALL-2016 protocol, this open-label,
      two-arm, multi-site trial PDT-Ph-like-ALL is aimed to evaluate the safety and effect of oral
      histone deacetylase inhibitor chidamide and dasatinib for adult Ph-like ALL.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Ph-like, or BCR-ABL1-like lymphoblastic leukemia is neoplasm of lymphoblasts committed to the
      B-cell lineage that lack the BCR-ABL1 translocation but show a pattern of the expression very
      similar to that seen in BCR-ABL1-positive ALL. Chidamide is a novel oral HDACi with promising
      activity in non-Hodgkin lymphoma (NHL). Based on the pediatric-inspired,
      PEG-L-asparaginase-intensified and MRD-directed PDT-ALL-2016 protocol, this open-label,
      two-arm, multi-site trial is aimed to evaluate the safety and effect of oral histone
      deacetylase inhibitor (HDACi) chidamide and tyrosine kinase inhibitor (TKI) dasatinib for
      adult Ph-like ALL/LBL. HDACi chidamide and TKI dasatinib will be added to chidamide and
      dasatinib group, respectively, from induction therapy to consolidation therapy (total courses
      of chidamide treatment: 5 courses for allo-HSCT after Consolidation Module-3; 12 courses for
      patients non-allo-HSCT after Consolidation Module 1-9). Primary study endpoint is event-free
      survival and secondary study endpoints are complete remission and MRD after induction,
      adverse event and overall survival.

      Pretreatment: Dexamethasone, -3 to 0d;

      Chidamide for chidamide arm: 10mg/d, po qd.

      Dasatinib for Dasatinib arm: 100mg/d, po qd.

      Induction:VCR: 1, 8, 15, 22; IDA: 1, 8; CTX: 1g/m2, 1; PEG-asp: 2000-2500IU/m2, 1, 15; Pred:
      1-24;

      MRD assessment: d14, 24, 45, and pre-allo-HSCT.

      VLCAM (MRD1/d14&gt;1%): CTX, d25; AraC 50mg/m2, d25-31, 26; 6-MP: 25-31, PEG-asp: 26;

      Consolidation Module:

      CM1: AraC 2g/m2, q12h, 1-2, Dex: 10mg/m2, 1-2, PEG-asp: 2, 6-MP: 1-7. IT: d1; CM2: MTX 3g/m2,
      1, Dex: 10mg/m2, 1-2, PEG-asp: 2; 6-MP: 1-7; IT: d1; CM3: CTX 0.5g/m2, 1-3, PEG-asp: 2, 6-MP:
      1-7, IT: d1.

      Allo-HSCT: after CM3 when donors available. Non-HSCT: finish CM 4-9 and POMP maintenance.

      CM4-6: repeat CM1-3. Re-Induction: after CM6. CM7-9: repeat CM1-3.

      Maintenance: POMP-Pred: x12m; VCR x12m; MTX: x24m; 6-MPx24m.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 14, 2016</start_date>
  <completion_date type="Anticipated">August 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">May 30, 2020</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Event free survival</measure>
    <time_frame>3 years</time_frame>
    <description>EFS of Ph-like ALL group</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Minimum residual disease after induction</measure>
    <time_frame>3 months</time_frame>
    <description>MRD after 1 course</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CR after Induction Therapy</measure>
    <time_frame>3 months</time_frame>
    <description>CR rate of Ph-like group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death in induction</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>3 years</time_frame>
    <description>AE during PDT-Ph-like</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relapse</measure>
    <time_frame>3 years</time_frame>
    <description>Relapse of Ph-like ALL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relapse free survival</measure>
    <time_frame>3 years</time_frame>
    <description>RFS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>3 years</time_frame>
    <description>OS</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Leukemia</condition>
  <condition>Leukemia, Acute</condition>
  <condition>Leukemia, Lymphoblastic</condition>
  <condition>Leukemia, B-cell</condition>
  <arm_group>
    <arm_group_label>Chidamide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Chidamide will be added to chidamide arm Ph-like ALL(CRLF2 high-expression, CRLF2/EPO/JAK2 rearrangement, JAK/IL-7R/SH2B3 mutation, etc).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dasatinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dasatinib at a dose of 100mg/day will be added to Dasatinib arm of Ph-like ALL (CRKL high-expression, ABL1 or ABL2 or CSFR1 or PRGFRB rearrangement, etc).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chidamide</intervention_name>
    <description>Chidamide will be administrated at dose of 10mg/day in chidamide arm in PDT-Ph-Like protocol. PDT-Ph-Like protocol for chidamide arm consists of diagnostic test (bone marrow aspiration, flow immunophenotyping, karyotyping，FISH, NGS, Flow-MRD), induction regimen (chidamide, prednisone, vincristine, cyclophosphamide, idarubicin, pegaspargase), consolidation regimen (chidamide, cytarabine, methotrexate, dexamethasone, cyclophosphamide, etoposide, 6-mercaptopurine, pegaspargase), MRD assessment and maintenance regimen, intrathecal injection chemotherapy, radiation therapy for CNS-involved leukemia and allogeneic hematopoietic stem cell transplantation.</description>
    <arm_group_label>Chidamide</arm_group_label>
    <other_name>HDACi chidamide</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dasatinib</intervention_name>
    <description>Dasatinib will be administrated at a dose of 100mg/day in dasatinib arm in PDT-Ph-Like protocol. PDT-Ph-Like protocol for dasatinib arm consists of diagnostic test (bone marrow aspiration, flow immunophenotyping, karyotyping，FISH, NGS, Flow-MRD), induction regimen (dasatinib, prednisone, vincristine, cyclophosphamide, idarubicin, pegaspargase), consolidation regimen (dasatinib, cytarabine, methotrexate, dexamethasone, cyclophosphamide, etoposide, 6-mercaptopurine, pegaspargase), MRD assessment and maintenance regimen, intrathecal injection chemotherapy, radiation therapy for CNS-involved leukemia and allogeneic hematopoietic stem cell transplantation.</description>
    <arm_group_label>Dasatinib</arm_group_label>
    <other_name>TKI dasatinib</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  14-55 years old;

          -  Ph-like ALL newly diagnosed;

          -  signed written informed consent

        Exclusion Criteria:

          -  Pregnant women;

          -  History of pancreatitis;

          -  History of diabetes;

          -  History of active peptic ulcer disease in the past 6 months;

          -  History of arteriovenous thrombosis in the past 6 months;

          -  Severe active infection;

          -  Allergic to any drugs in PDT-Ph-like-ALL.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>14 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Hongshengq Zhou, MD, Ph.D</last_name>
    <phone>86-20-62787349</phone>
    <email>zhs1@i.smu.edu.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Hematology, Nanfang Hospital</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510515</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hongsheng Zhou, PhD, MD</last_name>
      <phone>86-20-62787349</phone>
      <email>zhs1@i.smu.edu.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2018</verification_date>
  <study_first_submitted>June 9, 2018</study_first_submitted>
  <study_first_submitted_qc>June 11, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 20, 2018</study_first_posted>
  <last_update_submitted>June 11, 2018</last_update_submitted>
  <last_update_submitted_qc>June 11, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">June 20, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Nanfang Hospital of Southern Medical University</investigator_affiliation>
    <investigator_full_name>Qifa Liu</investigator_full_name>
    <investigator_title>M.D., Professor</investigator_title>
  </responsible_party>
  <keyword>Acute Lymphoblastic Leukemia</keyword>
  <keyword>Ph-like</keyword>
  <keyword>Tyrosine Kinase Inhibitor</keyword>
  <keyword>Histone Deacetylase Inhibitor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, B-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dasatinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

